Research Papers:

Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer

Angel Chao _, Ting-Chang Chang, Nina Lapke, Shih-Ming Jung, Peter Chi, Chien-Hung Chen, Lan-Yan Yang, Cheng-Tao Lin, Huei-Jean Huang, Hung-Hsueh Chou, Jui-Der Liou, Shu-Jen Chen, Tzu-Hao Wang and Chyong-Huey Lai

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:85529-85541. https://doi.org/10.18632/oncotarget.13456

Metrics: PDF 2986 views  |   HTML 3716 views  |   ?  


Angel Chao1,2,*, Ting-Chang Chang1,2,*, Nina Lapke3,*, Shih-Ming Jung4, Peter Chi5, Chien-Hung Chen3, Lan-Yan Yang6, Cheng-Tao Lin1,2, Huei-Jean Huang1,2, Hung-Hsueh Chou1,2, Jui-Der Liou1,2, Shu-Jen Chen3, Tzu-Hao Wang1,2,7, Chyong-Huey Lai1,2

1Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan

2Gynecologic Cancer Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan

3ACTGenomics, Co. Ltd., Taiwan

4Department of Pathology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan

5Institute of Biochemical Sciences, College of Life Science, National Taiwan University, Taiwan

6Clinical Trial Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan

7School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan

*These authors have contributed equally to this work

Correspondence to:

Shu-Jen Chen, email: [email protected]

Tzu-Hao Wang, email: [email protected]

Chyong-Huey Lai, email: [email protected]

Keywords: BRCA1/2, germline mutations, somatic mutations, ovarian cancer

Received: August 20, 2016     Accepted: October 28, 2016     Published: November 19, 2016


Germline and somatic BRCA1/2 mutations define a subset of patients with ovarian cancer who may benefit from treatment with poly (ADP-ribose) polymerase inhibitors. Unfortunately, data on the frequency of BRCA1/2 germline mutations in Taiwanese patients with ovarian cancer are scarce, with the prevalence of somatic mutations being unknown. We aim to investigate the occurrence of BRCA1/2 mutations in 99 Taiwanese patients with ovarian cancer which included serous (n = 46), endometrioid (n = 24), and clear cell (n = 29) carcinomas. BRCA1/2 mutations were identified using next-generation sequencing of formalin-fixed paraffin-embedded tumor samples. Pathogenic variants (BRCA1: n = 7; BRCA2: n = 6) were detected in 12.1% (12/99) of the study patients. Somatic and germline BRCA1/2 mutation rates in serous ovarian cancer are 4/46 (8.7%) and 8/46 (17%), respectively. All of the pathogenic BRCA1/2 mutations were identified in serous carcinoma samples (12/46; 26.1%). One-third (4/12) of the deleterious BRCA1/2 mutations occurred in tumor tissues only (somatic mutations). All of them coexisted with loss of heterozygosity, resulting in biallelic BRCA inactivation. Five novel pathogenic mutations were identified, including four somatic variants (BRCA1 p.S242fs, BRCA1 p.F989fs, BRCA1 p.G1738fs, and BRCA2 p.D1451fs) and a germline variant (BRCA2 p.E260fs). We also detected additional six novel mutations (three in BRCA1 and three in BRCA2) with pathogenic potentials. We conclude that BRCA1/2 mutations are common in Taiwanese patients with serous ovarian carcinoma and similar to mutation rates in other ethnic groups. The analysis of BRCA1/2 somatic mutations is crucial for guiding therapeutic decisions in ovarian cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13456